NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
2.640
-0.140 (-5.04%)
At close: Jan 28, 2026, 4:00 PM EST
2.640
0.00 (0.00%)
After-hours: Jan 28, 2026, 4:00 PM EST
NewcelX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
12.19M USD
Revenue Chart
* This company reports financials in ILS.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 12.74M |
| Curis | 11.65M |
| Bolt Biotherapeutics | 5.20M |
| Longeveron | 1.44M |
| CytoMed Therapeutics | 573.19K |
NCEL News
- 16 days ago - NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression - PRNewsWire
- 23 days ago - NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - PRNewsWire
- 6 weeks ago - NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - PRNewsWire
- 2 months ago - NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - PRNewsWire
- 2 months ago - NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - PRNewsWire
- 3 months ago - NewcelX CEO Issues Letter to Shareholders - PRNewsWire
- 3 months ago - NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. - PRNewsWire